Claims

1. Use of *Crassocephalum rabens* plant or extract or galactolipid compounds from *Crassocephalum rabens* or a pharmaceutically acceptable derivative thereof and optionally a pharmaceutically acceptable carrier or excipient in the manufacture of a medicament for inducing humoral immune response in a subject in need.
2. The use according to claim 1, wherein the medicament is for attracting B cells, enhancing antibody production, enhancing antibody class switching, inducing antibody-dependent cell cytotoxicity, inducing antibody-dependent cell phagocytosis, increasing serum IFN-γ and IL-21, inducing B cell proliferation, or inducing B cell differentiation.
3. The use according to claim 2, wherein the antibody class switching comprises switching from IgM to IgG1, IgG2 or IgG3.
4. The use according to claim 2, wherein the medicament is for inducing B cell proliferation or inducing B cell differentiation through IL-21R/STAT3/Blimp-1 pathway.
5. The use according to claim 1, wherein the humoral immune response is induced against a surface-bound cancer antigen; or an antigen associated with a neurodegenerative disease.
6. The use according to claim 5, wherein the cancer is drug-resistant colorectal cancer.
7. The use according to claim 1, wherein the Crassocephalum rabens is *Crassocephalum rabens* (*Benth*.) *S. Moore*.
8. The use according to claim 1, wherein the *Crassocephalum rabens* plant is pieces of dried or fresh *Crassocephalum rabens*.
9. The use according to claim 1, wherein the *Crassocephalum rabens* extract is alcohol extract of *Crassocephalum rabens*.
10. The use according to claim 1, wherein the *Crassocephalum rabens* extract is manufactured by extracting *Crassocephalum rabens* with an alcohol solution to obtain alcohol extract; fractioning the alcohol extract to obtain a phytogalactolipid-enriched fraction.
11. The use according to claim 10, wherein the fractioning step is performed with reverse phase medium pressure liquid chromatography (RP-MPLC).
12. The use according to claim 11, wherein reverse phase high performance liquid chromatography (RP-HPLC) is further performed after RP-MPLC.
13. The use according to claim 1, wherein the galactolipid compound is 1,2-di-*O*-α-linolenoyl-3-*O*-β-galactopyranosyl-sn-glycerol (dLGG) or 1,2-di-(α-linolenoyl)-3-[α-D-galactosyl-(1-6)-β-D-galactosyl]-sn-glycerol (CRDG).

14. An adjuvant composition comprising an effective amount of *Crassocephalum rabens* plant or extract or galactolipid compounds from *Crassocephalum rabens* or a pharmaceutically acceptable derivative thereof.
15. The adjuvant composition according to claim 14, wherein the *Crassocephalum rabens* is *Crassocephalum rabens (Benth.) S. Moore*.
16. The adjuvant composition according to claim 14, wherein the *Crassocephalum rabens* plant is pieces of dried or fresh *Crassocephalum rabens.*
17. The adjuvant composition according to claim 14, wherein the *Crassocephalum rabens* extract is alcohol extract of *Crassocephalum rabens*.
18. The adjuvant composition according to claim 14, wherein the *Crassocephalum rabens* extract is manufactured by extracting *Crassocephalum rabens* with an alcohol solution to obtain alcohol extract; fractioning the alcohol extract to obtain a phytogalactolipid-enriched fraction.
19. The adjuvant composition according to claim 18, wherein the fractioning is performed with reverse phase medium pressure liquid chromatography (RP-MPLC).
20. The adjuvant composition according to claim 19, wherein reverse phase high performance liquid chromatography (RP-HPLC) is further performed after RP-MPLC.
21. The adjuvant composition according to claim 14, wherein the galactolipid compound is 1,2-di-*O*-α-linolenoyl-3-*O*-β-galactopyranosyl-*sn*-glycerol (dLGG) or 1,2-di-(α-linolenoyl)-3-[α-D-galactosyl-(1-6)-β-D-galactosyl]-*sn*-glycerol (CRDG).
22. An immunogenic composition comprising an antigen component and the adjuvant composition according to claim 14.
23. The immunogenic composition according to claim 22, wherein the antigen component is a peptide or a protein.
24. Use of the adjuvant composition according to any of claims 14 to 21 or the immunogenic composition according to claim 22 or 23 in the manufacture of a medicament for enhancing immune response in a subject in need.
25. The use according to claim 24, wherein the adjuvant composition or the immunogenic composition is administered through an oral route.
26. The use according to claim 24, wherein the medicament is for enhancing antibody production, enhancing antibody class switching, increasing the proportion of IgG2a, IgG2b or IgG3 in total IgG antibodies, triggering IL-21 and/or B cell activating factor (BAFF) release, triggering B cell differentiation, enhancing cell proliferation, uptake ability, and/or antigen presentation of phagocytes, or increasing Th1 and Th2-related immune responses.